化合物 Rociletinib|T2369|TargetMol

Rociletinib
1374640-70-6

￥415 5mg 起订

￥679 10mg 起订

￥1246 50mg 起订

上海更新日期：2024-09-24

TargetMol中国（陶术生物）

VIP12年

联系人：邵小姐

电话：021-021-33632979拨打

手机：15002134094 拨打

邮箱：marketing@targetmol.com

产品详情:

中文名称：: 化合物 Rociletinib

英文名称：: Rociletinib

CAS号：: 1374640-70-6

品牌：: TargetMol

产地：: 美国

保存条件：: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.

纯度规格：: 99.25%

产品类别：: 抑制剂

货号：: T2369

Product Introduction

Bioactivity

Name	Rociletinib
Description	Rociletinib (CNX-419) is an orally available small molecule, irreversible inhibitor of epidermal growth factor receptor (EGFR) with potential antineoplastic activity.
Cell Research	Cells are seeded at 3,000 cells per well in growth media supplemented with 5% FBS, 2 mmol/L, L-glutamine, and 1% penicillin–streptomycin, allowed to adhere overnight, and treated with a dilution series of test compounds for 72 hours. Cell viability is determined by CellTiter-Glo, and results are represented as background-subtracted relative light units normalized to a dimethyl sulfoxide (DMSO)–treated control. Growth inhibition (GI 50) values are determined by GraphPad Prism 5.04. MK-2206 and XL-880 compounds are obtained from Selleck Chemical. CI data are generated using CalcuSyn.(Only for Reference)
Kinase Assay	Inhibition Kinetics Studies: Recombinant human wild-type and T790M/L858R double mutant EGFR, both Nterminal GST-tagged, are used in the assay. The Omnia continuous read assay is performed as described by the vendor.
In vitro	CO-1686在所有EGFR突变体模型以及表达EGFRL858R-和EGFRL858R/T790M的转基因小鼠中引起显著的剂量依赖性肿瘤生长抑制.
In vivo	CO-1686选择性抑制NSCLC细胞表达的突变体EGFR的生长,GI50范围为7 到 32 nM,并诱导细胞凋亡。耐CO-1686的NSCLC细胞系表现出上皮 - 间充质转变的迹象并且对AKT抑制剂的敏感性增加。CO-1686在表达突变型EGFR的细胞中抑制p-EGFR,其IC50范围为62至187 nM,同时在三种WT EGFR表达细胞中抑制EGFR磷酸化,IC50> 2,000 nM。
Storage	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
Solubility Information	Ethanol : < 1 mg/mL (insoluble or slightly soluble) DMSO : 93 mg/mL (167.4 mM) H2O : < 1 mg/mL (insoluble or slightly soluble)
Keywords	CNX 419 \| AVL 301 \| HER1 \| Inhibitor \| inhibit \| CO 1686 \| EGFR \| ErbB-1 \| Rociletinib \| AVL301 \| CNX419 \| Epidermal growth factor receptor \| CO1686
Inhibitors Related	Lapatinib \| Neratinib \| Chalcone \| Gefitinib \| Erlotinib \| Osimertinib \| Erlotinib hydrochloride \| Afatinib Dimaleate \| Lidocaine Hydrochloride hydrate \| Genistein \| Khellin \| Osimertinib mesylate
Related Compound Libraries	Inhibitor Library \| Anti-Cancer Approved Drug Library \| Anti-Cancer Active Compound Library \| Bioactive Compounds Library Max \| Kinase Inhibitor Library \| Highly Selective Inhibitor Library \| Membrane Protein-targeted Compound Library \| Drug Repurposing Compound Library \| Tyrosine Kinase Inhibitor Library \| FDA-Approved Kinase Inhibitor Library

CO-1686|||CNX-419|||AVL-301|TargetMol

上海陶术生物科技有限公司为美国Target Molecule Corp. ( Target Mol ) 在上海建立的全资子公司。我们与美国波士顿、德国慕尼黑的同事一起，为北美、欧洲和亚洲从事药物研发和生物学研究的科学家提供优质的产品和专业的服务。公司下设筛选事业部，化学事业部，生物事业部和新材料部。从虚拟筛选到实体化合物分子供应；从商业化产品销售到个性化定制合成；从对明确靶点的分子筛选到对明确分子的多靶点筛选，从高通量筛选到化学结构优化，我们都可以满足您的科研用品及技术服务的需求。经过在中国市场五年的精心耕耘，我们已成为筛选化合物领域优秀的供应商，为超过五百家学校和各类企业提供了品质卓越的小分子化合物和药物筛

成立日期	(12年)
注册资本	566.2651万人民币
员工人数	100-500人
年营业额	￥ 1亿以上
经营模式	贸易,试剂,定制,服务
主营行业	化学试剂,生物活性小分子